155 related articles for article (PubMed ID: 22307932)
1. Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.
Diez-Torrubia A; Cabrera S; Lambeir AM; Balzarini J; Camarasa MJ; Velázquez S
ChemMedChem; 2012 Apr; 7(4):618-28. PubMed ID: 22307932
[TBL] [Abstract][Full Text] [Related]
2. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.
Diez-Torrubia A; García-Aparicio C; Cabrera S; De Meester I; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2010 Jan; 53(2):559-72. PubMed ID: 20000418
[TBL] [Abstract][Full Text] [Related]
3. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S
J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV-activated prodrugs of anti-varicella zoster virus bicyclic nucleoside analogues containing different self-cleavage spacer systems.
Diez-Torrubia A; Cabrera S; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
ChemMedChem; 2012 Sep; 7(9):1612-22. PubMed ID: 22887971
[TBL] [Abstract][Full Text] [Related]
6. Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26).
García-Aparicio C; Diez-Torrubia A; Balzarini J; Lambeir AM; Velázquez S; Camarasa MJ
Antiviral Res; 2007 Nov; 76(2):130-9. PubMed ID: 17675255
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
García-Aparicio C; Bonache MC; De Meester I; San-Félix A; Balzarini J; Camarasa MJ; Velazquez S
J Med Chem; 2006 Aug; 49(17):5339-51. PubMed ID: 16913724
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-peptidase IV (DPP IV/CD26)-activated prodrugs: a successful strategy for improving water solubility and oral bioavailability.
Velázquez S; de Castro S; Diez-Torrubia A; Balzarini J; Camarasa MJ
Curr Med Chem; 2015; 22(8):1041-54. PubMed ID: 25620096
[TBL] [Abstract][Full Text] [Related]
9. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.
Aertgeerts K; Ye S; Shi L; Prasad SG; Witmer D; Chi E; Sang BC; Wijnands RA; Webb DR; Swanson RV
Protein Sci; 2004 Jan; 13(1):145-54. PubMed ID: 14691230
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers.
Dahan A; Wolk O; Yang P; Mittal S; Wu Z; Landowski CP; Amidon GL
Mol Pharm; 2014 Dec; 11(12):4385-94. PubMed ID: 25365774
[TBL] [Abstract][Full Text] [Related]
11. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs.
Krise JP; Zygmunt J; Georg GI; Stella VJ
J Med Chem; 1999 Aug; 42(16):3094-100. PubMed ID: 10447953
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats.
Alponti RF; Frezzatti R; Barone JM; Alegre Vde S; Silveira PF
Metabolism; 2011 Feb; 60(2):234-42. PubMed ID: 20153005
[TBL] [Abstract][Full Text] [Related]
13. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
Durinx C; Lambeir AM; Bosmans E; Falmagne JB; Berghmans R; Haemers A; Scharpé S; De Meester I
Eur J Biochem; 2000 Sep; 267(17):5608-13. PubMed ID: 10951221
[TBL] [Abstract][Full Text] [Related]
15. Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine--synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid.
Nielsen AB; Buur A; Larsen C
Eur J Pharm Sci; 2005 Apr; 24(5):433-40. PubMed ID: 15784333
[TBL] [Abstract][Full Text] [Related]
16. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator.
Fan H; Tansi FL; Weihofen WA; Böttcher C; Hu J; Martinez J; Saenger W; Reutter W
Eur J Cell Biol; 2012 Apr; 91(4):265-73. PubMed ID: 21856036
[TBL] [Abstract][Full Text] [Related]
18. Influence of dipeptidyl peptidase IV on enzymatic properties of adenosine deaminase.
Sharoyan S; Antonyan A; Mardanyan S; Lupidi G; Cristalli G
Acta Biochim Pol; 2006; 53(3):539-46. PubMed ID: 16929383
[TBL] [Abstract][Full Text] [Related]
19. The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery.
Ackaert OW; De Graan J; Capancioni R; Della Pasqua OE; Dijkstra D; Westerink BH; Danhof M; Bouwstra JA
J Control Release; 2010 Jun; 144(3):296-305. PubMed ID: 20230864
[TBL] [Abstract][Full Text] [Related]
20. Novel prodrugs with a spontaneous cleavable guanidine moiety.
Hamada Y
Bioorg Med Chem Lett; 2016 Apr; 26(7):1685-9. PubMed ID: 26923694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
